Corrected QT (QTc) Study With Flucticasone Furoate and GW642444
Status:
Completed
Trial end date:
2011-01-04
Target enrollment:
Participant gender:
Summary
A randomised, placebo controlled thorough QTc study to evaluate the effect of repeat dose
FF/GW642444M combination, with moxifloxacin as a positive control, on the QTc interval in
healthy male and female subjects. Key assessments will include 12- lead electrocardiogram
(ECG) and pharmacokinetic (PK) parameters, along with safety being assessed by blood
pressure, heart rate, clinical laboratory safety tests, and collection of adverse events.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluoroquinolones Fluticasone Moxifloxacin Norgestimate, ethinyl estradiol drug combination Xhance